Stockscreener 앱 받기
15.47
3.06%
0.46
시간 외 거래:
15.47
전일 마감가:
$15.01
열려 있는:
$15
하루 거래량:
1.67M
Relative Volume:
1.05
시가총액:
$1.70B
수익:
$-249.00K
순이익/손실:
$-187.60M
주가수익비율:
-6.188
EPS:
-2.5
순현금흐름:
$-201.88M
1주 성능:
-6.53%
1개월 성능:
+25.47%
6개월 성능:
+89.82%
1년 성능:
+343.27%
1일 변동 폭
$14.85
$15.79
1주일 범위
$14.85
$17.49
52주 변동 폭
$2.865
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
15.47 | 1.65B | -249.00K | -187.60M | -201.88M | -2.50 |
|
ZTS
Zoetis Inc
|
124.96 | 54.61B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.91 | 52.47B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.42 | 46.18B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.53 | 36.87B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.78 | 20.38B | 3.08B | 1.24B | 1.07B | 25.61 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha
FY2030 Earnings Estimate for AMLX Issued By HC Wainwright - MarketBeat
Is Amylyx Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Chart Watch & Entry Point Strategy Guides - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amylyx nominates AMX0318 as long-acting GLP-1 candidate for rare endocrine disorders - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5%What's Next? - MarketBeat
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Yahoo Finance
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 By Investing.com - Investing.com Nigeria
Amylyx Pharma Hits New HighDelivers Over 160% Gain In 7 Months - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighTime to Buy? - MarketBeat
January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 - Investing.com
Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update - simplywall.st
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com Australia
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock By Investing.com - Investing.com India
Amylyx pharma co-CEO Cohen sells $1.87m in shares By Investing.com - Investing.com India
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $1,850,862.87 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $27,300.42 in Stock - MarketBeat
Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading 11.7% HigherHere's What Happened - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 8.85% on Jan 20 - GuruFocus
EV Market: Is Amylyx Pharmaceuticals Inc stock a good pick for beginnersWeekly Stock Recap & Pattern Based Trade Signal System - baoquankhu1.vn
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Finviz
More Money In The Bank For Amylyx Pharmaceuticals Insiders Who Divested US$2.0m - 富途牛牛
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases - Finviz
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuation2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside - TipRanks
How Amylyx Pharmaceuticals’ (AMLX) Move Into GLP-1 Rare Diseases Has Changed Its Investment Story - Sahm
Amylyx selects AMX-0318 as development candidate - BioWorld MedTech
Amylyx selects AMX0318 as development candidate for PBH - Yahoo Finance
Is Amylyx Pharmaceuticals Inc. stock recession proofJuly 2025 Reactions & Stepwise Entry/Exit Trade Alerts - Улправда
Why Amylyx Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Community Consensus Stock Picks - Улправда
Top Amylyx Executives Quietly Cash Out in Coordinated Stock Moves - TipRanks
James Frates Sells 3,326 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program By Investing.com - Investing.com Nigeria
Mizuho reiterates Outperform rating on Amylyx stock, cites GLP-1 program - Investing.com Australia
US company unveils candidate for Gubra partnership - medwatch.com
Amylyx Advances AMX0318 as New Rare-Disease Candidate - TipRanks
Amylyx Pharmaceuticals, Inc. Announces Development of AMX0318 - TradingView — Track All Markets
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.51%
9.76%
자본화:
|
볼륨(24시간):